Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England.
Anti Veg-F medicines are currently used in the treatment of:
a. neovascular (wet) age-related macular degeneration (AMD);
b. visual impairment due to diabetic macular oedema (DME/DMO);
c. visual impairment due to myopic choroidal neovascularisation (myopic CNV); and d. visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).
Period of framework: 1 April 2023 to 31 March 2024 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 24 months)
Framework Reference Number: CMD/SCM/MJP/2023/01
Atamis Reference Number: C123966 http://health.atamis.co.uk/
No supplier information available.